Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer.


:The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidation treatment has been put forward, whereby systemically active doses of chemotherapy, targeted therapy or immune therapy are administered after completion of radiochemotherapy. Randomized trials failed to provide support for consolidation chemotherapy or anti-EGFR therapies. Recently durvalumab, an anti-PD-L1 checkpoint inhibitor, administered as consolidation treatment, was shown to substantially improve progression-free survival. This article critically reviews major studies addressing the role of consolidation systemic therapies following definitive concurrent radiochemotherapy and discusses prospects for future research.


Cancer Treat Rev


Cancer treatment reviews


Skrzypski M,Jassem J




Has Abstract


2018-05-01 00:00:00












  • The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.

    abstract::Dysregulated activation of the MET tyrosine kinase receptor is implicated in the development of solid tumors and can arise through several mechanisms, including gene amplification, overexpression of the receptor and/or its ligand hepatocyte growth factor (HGF), and the acquisition of activating mutations. The most com...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Salgia R,Sattler M,Scheele J,Stroh C,Felip E

    更新日期:2020-07-01 00:00:00

  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

    abstract::Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

    更新日期:2016-11-01 00:00:00

  • How did lomustine become standard of care in recurrent glioblastoma?

    abstract::Glioblastomas are the most common malignant primary intrinsic brain tumors. Their incidence increases with age, and males are more often affected. First-line management includes maximum safe surgical resection followed by involved-field radiotherapy plus concomitant and six cycles of maintenance temozolomide chemother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Weller M,Le Rhun E

    更新日期:2020-07-01 00:00:00

  • Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.

    abstract:BACKGROUND:The incidence of brain metastases (BM) in melanoma patients is common and associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint blockade antibodies led to improved survival of metastatic melanoma patients; however, patients with BM are under-represented or excluded from the majorit...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Spagnolo F,Picasso V,Lambertini M,Ottaviano V,Dozin B,Queirolo P

    更新日期:2016-04-01 00:00:00

  • Participation of adolescents with cancer in clinical trials.

    abstract::Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Ferrari A,Bleyer A

    更新日期:2007-11-01 00:00:00

  • The role of PET/CT in the modern treatment of Hodgkin lymphoma.

    abstract::Classical Hodgkin Lymphoma is distinguished from other lymphomas by its peculiar biology and heterogeneous chemosensitivity. Most of the patients respond to the standard first-line treatment and are cured, however, in selected cases, the disease relapses or remains primarily refractory. Among predictive/prognostic fac...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Zaucha JM,Chauvie S,Zaucha R,Biggii A,Gallamini A

    更新日期:2019-07-01 00:00:00

  • The potential of melanoma antigen expression in cancer therapy.

    abstract::A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Gillespie AM,Coleman RE

    更新日期:1999-08-01 00:00:00

  • Can we better manage Unfit older cancer patients?

    abstract::The term Unfit refers to older cancer patients not amenable with standard treatment and needing therefore a modified or attenuated treatment or also not deserving an active therapeutic approach. To determine whether an old patient is Unfit a Multidimensional Geriatric Evaluation is needed, but to spare time, shortened...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Monfardini S

    更新日期:2009-10-01 00:00:00

  • SARS-CoV-2 and cancer: Are they really partners in crime?

    abstract::The outbreak of the SARS-CoV-2 pandemic has overwhelmed health care systems in many countries. The clinical presentation of the SARS-CoV-2 varies between a subclinical or flu-like syndrome to that of severe pneumonia with multi-organ failure and death. Initial reports have suggested that cancer patients may have a hig...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: van Dam PA,Huizing M,Mestach G,Dierckxsens S,Tjalma W,Trinh XB,Papadimitriou K,Altintas S,Vermorken J,Vulsteke C,Janssens A,Berneman Z,Prenen H,Meuris L,Vanden Berghe W,Smits E,Peeters M

    更新日期:2020-09-01 00:00:00

  • Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer.

    abstract::Epithelial ovarian cancer (EOC) is the most common gynaecological malignancy in the Western world and a leading cause of death. Patients with relapsed EOC are incurable and therefore the toxicity of palliative chemotherapy and effects on health-related Quality of Life are important factors. Several newer cytotoxic age...

    journal_title:Cancer treatment reviews

    pub_type: 临床试验,杂志文章,随机对照试验,评审


    authors: Stebbing J,Gaya A

    更新日期:2002-04-01 00:00:00

  • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

    abstract:BACKGROUND:The second decade of 2000s is witnessing a new ovarian cancer (OC) paradigm shift thanks to the results recently obtained by a new class of targeted agents: the Poly(ADP-ribose)polymerase (PARP)-Inhibitors (PARPi). Aim of this meta-analysis is to analyze available results obtained with PARPi, administered al...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析


    authors: Ruscito I,Bellati F,Ray-Coquard I,Mirza MR,du Bois A,Gasparri ML,Costanzi F,De Marco MP,Nuti M,Caserta D,Pignata S,Dorigo O,Sehouli J,Braicu EI

    更新日期:2020-07-01 00:00:00

  • Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

    abstract::Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpress...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Ocaña A,Amir E

    更新日期:2009-12-01 00:00:00

  • Pancreatic cancer: current and future treatment strategies.

    abstract::Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Pliarchopoulou K,Pectasides D

    更新日期:2009-08-01 00:00:00

  • Targeted therapeutic approaches for hormone-refractory prostate cancer.

    abstract::Prostate cancer is one of the leading causes of cancer related death in men, and remains incurable in the metastatic setting. Despite the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state due to cumulative genetic alterations in tumour cells or the microenvironmen...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Stavridi F,Karapanagiotou EM,Syrigos KN

    更新日期:2010-04-01 00:00:00

  • Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy.

    abstract::Twenty patients with malignant lymphomas refractory to prior combination chemotherapy were treated with ifosfamide (40 mg/kg/day i.v. days 1-5) and etoposide (120 mg/m2/day i.v., days 1, 3, 5). Altogether, 56 courses of treatment were given with prophylaxis of urinary side effects by mesna (8 mg/kg i.v. 0, 4, 8 hours ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Scheulen ME,Bremer K,Niederle N,Seeber S

    更新日期:1983-09-01 00:00:00

  • Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.

    abstract::Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Liu S,Kurzrock R

    更新日期:2014-08-01 00:00:00

  • Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?

    abstract::The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: ER(+)/PgR(+), ER(-)/PgR(-), ER(+)/PgR(-) and ER(-)/PgR(+). The existence of the latter...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Kunc M,Biernat W,Senkus-Konefka E

    更新日期:2018-06-01 00:00:00

  • Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?

    abstract::In the last few years, several drugs targeting signalling proteins critical for melanoma entered clinical evaluation. In 2011 vemurafenib (Zelboraf®, F. Hoffman-La Roche Ltd.) was approved for BRAF V600-positive melanoma and showed high overall response rates (48-53%). However recent results from a phase II clinical t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Nijenhuis CM,Haanen JB,Schellens JH,Beijnen JH

    更新日期:2013-06-01 00:00:00

  • Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology.

    abstract:PURPOSE:Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Russi EG,Corvò R,Merlotti A,Alterio D,Franco P,Pergolizzi S,De Sanctis V,Ruo Redda MG,Ricardi U,Paiar F,Bonomo P,Merlano MC,Zurlo V,Chiesa F,Sanguineti G,Bernier J

    更新日期:2012-12-01 00:00:00

  • Bisantrene, biological and clinical effects.

    abstract::The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Coltman CA Jr,Osborne CK

    更新日期:1984-12-01 00:00:00

  • A preclinical and clinical review of aflibercept for the management of cancer.

    abstract::Aflibercept, also known as vascular endothelial growth factor (VEGF)-Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only all forms of VEGF-A, but also VEGF-B and placental growth factor. It inhibits VEGF-induced angiogenesis in preclinical models. In t...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Gaya A,Tse V

    更新日期:2012-08-01 00:00:00

  • Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

    abstract::Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients with locally advanced or metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Custodio A,Puente J,Sastre J,Díaz-Rubio E

    更新日期:2009-12-01 00:00:00

  • Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Solinas C,Ceppi M,Lambertini M,Scartozzi M,Buisseret L,Garaud S,Fumagalli D,de Azambuja E,Salgado R,Sotiriou C,Willard-Gallo K,Ignatiadis M

    更新日期:2017-06-01 00:00:00

  • Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.

    abstract::Pancreatic cancer represents the fourth leading cause of cancer death in men and the fifth in women. Prognosis remains dismal, mainly because the diagnosis is made late in the clinical course of the disease. The need to improve the diagnosis, detection, and treatment of pancreatic cancer is great. It is in this type o...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Sakorafas GH,Tsiotou AG,Tsiotos GG

    更新日期:2000-02-01 00:00:00

  • Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:Data on the comparative efficacy of fulvestrant and other endocrine treatments are inconsistent. Clinical markers predictive of greater benefit from fulvestrant compared to the alternate endocrine agents have not been identified. METHODS:We searched the literature from inception to May 2015, using MEDLINE, ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审


    authors: Graham J,Pitz M,Gordon V,Grenier D,Amir E,Niraula S

    更新日期:2016-04-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章


    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

    abstract::The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key chal...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Lim SM,Syn NL,Cho BC,Soo RA

    更新日期:2018-04-01 00:00:00

  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • Markers of bone turnover in prostate cancer.

    abstract::Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Garnero P

    更新日期:2001-06-01 00:00:00

  • The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies.

    abstract::Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审


    authors: Sakorafas GH

    更新日期:2003-04-01 00:00:00